The identification of mutations in the haemochromatosis gene (HFE) (C282Y and H63D) provides the unique opportunity to test whether genetic variants that are associated with tissue iron accumulation may influence the risk of coronary atherosclerosis. To this aim the prevalence of C282Y and H63D mutations was determined in 174 patients with angiographically documented CAD ( > 50% stenosis) and history of MI, 187 healthy free-living individuals and 142 blood donors. C282Y and H63D mutations were not found to be more frequent in coronary patients as compared to controls. Moreover, these HFE variants were unrelated to the severity of coronary atherosclerosis. These findings did not provide evidence of an association between HFE mutations and the presence of coronary atherosclerosis or its major ischaemic complications, thus indicating that HFE mutations are poor genetic markers of coronary risk. European Journal of Human Genetics (2000) 8, 389-392.
Introduction
The observation that iron increases free radical production and oxidative stress leads to the hypothesis that iron accumulation might contribute to in vivo LDL peroxidation and, thereby, to atherosclerosis. 1, 2 However, the relationship between iron status and atherosclerotic disease remains controversial. [3] [4] [5] [6] [7] [8] Body iron metabolism is, at least in part, genetically influenced, and the recent identification of the gene for hereditary haemochromatosis (HH) on chromosome 6 has significantly improved our understanding of the molecular basis of iron metabolism. 9 HH is an autosomal recessive disease that leads to progressive tissue iron accumulation and multiorgan dysfunction. 10 Two mutations have been detected in the HFE gene which are related to HH: C282Y and H63D. 11 The C282Y mutation was also found in a large majority of patients with sporadic porphyria cutanea tarda, 12 another condition associated with severe hepatic siderosis; thus it is considered a disease-causing mutation. The role of H63D is less defined and it seems to cause HH only when inherited together with the C282Y mutation. 13 However,
Garry et al 14 reported that healthy carriers of either mutation show increased levels of stored iron. This observation together with the relatively high frequency of HFE alleles in the general population 13 raised the possibility that heterozygosity for HFE mutations may significantly impact on the risk of atherosclerosis. The present investigation was designed with the objective to assess whether mutations in the HFE gene might be associated with increased risk of coronary artery disease (CAD).
Methods

Subjects
A total of 503 Italian subjects was included in the study. Case patients consisted of 174 consecutive patients, > 40 years old, with positive coronary angiograms (at least one vessel with > 50% stenosis) and a history of MI. Diagnosis of previous MI was verified by typical ECG changes and elevation of serum enzymes (CPK, AST and LDH). Patients with thyroid, liver or renal diseases were excluded. At the time of blood sampling, patients were under their usual cardiovascular medications. Two independent groups of subjects were evaluated as controls. The first group (population controls) included > 40-year-old, unrelated individuals randomly extracted from a population of 998 subjects participating in a community-based control programme of coronary risk factors. No preselection criteria were used. After selection, those (n = 187) with no evidence of CAD (no history of angina and normal resting ECG 15 ) were considered for genetic analysis.
The second group consisted of 145 individuals, 47 men and 98 women, (mean age 40 years) selected from a blood donor bank. No information on CAD status was available for blood donors. A structured questionnaire was used to characterise both case patients and population controls, as previously reported. 16 Clinical and biochemical characteristics of case patients and population controls are shown in Table 1 . With the exception of hypercolesterolaemia, population controls were characterised by a lower prevalence of major risk factors. Among population controls, 20 subjects (11%) were taking antihypertensive drugs and 25 subjects (13%) were taking lipid-lowering medications.
Fasting blood samples for routine laboratory examinations, lipid measurements and DNA isolation were obtained early in the morning after an overnight fast. Plasma total cholesterol and triglyceride, and HDL-cholesterol concentrations were measured as reported. 16 LDL cholesterol levels were calculated by the Friedewald formula.
Determination of HFE mutations
Detection of HFE mutations were performed by combination of PCR with an allele-specific oligonucleotide (ASO) technique. 17 PCR was performed using the following pairs of primers: 5'-TGGCAAGGGTAAACAGATCC-3' and 5'-CTCAGGCACTCCTCTCAACC-3' (for C282Y) and 5'-ACATGGTTAAGGCCTGTTGC-3' and 5'-GCCA-CATCTGGCTTGGAAATT-3' (for H63D) and carried out in 30 cycles consisting of 30 s at 94°C, 1 min at 60°C (55°C for the H63D mutation), 30 s at 72°C. Digoxigenin-labelled oligonucleotides for the detection of the C282Y mutation were: 5'-TATACGTGCCAGGT-3' (wild-type) and 5'-TATACG-TACCAGG-3' (mutant); those for the H63D detection were: 5'-CTATGATCATGAGAG-3' (wild-type) and 5'-CTATGATGAT-GAGAG-3' (mutant). The typical results for C282Y detection are reported in Figure 1 . Twenty samples were genotyped using both the ASO and the restriction enzyme technique; 11 concordance was 100%. 
Statistical analysis
Results
The prevalence of HFE mutations in case patients, population controls and blood donors is shown in Table 2 . In all groups, the frequencies of HFE genotypes were in Hardy-Weinberg equilibrium and did not show any difference according to age and sex. No homozygote for the C282Y mutation was found. Four CAD patients (2.3%) were heterozygous for the C282Y, but this frequency was not significantly different (P < 0.3) from that observed in both population controls (1.6%) and blood donors (4.3%). Both homozygous and Haemochromatosis gene and coronary atherosclerosis y heterozygous carriers for H63D mutations were detected. Although homozygosity for the H63D mutation tended to be higher in patients as compared with the control groups, the frequencies of the mutated D allele did not differ between the groups (P < 0.4). Two subjects were compound heterozygotes for both HFE mutations, but were detected among population controls (1.1%). Similar results were obtained when comparisons were made in men and women separately (data not shown).
With regard to CAD severity, patients without significantly diseased vessels showed similar frequency of HFE mutated alleles (0.8% for Y and 17.1% for D allele (compared with patients with one or two diseased vessels (1.5% for Y and 14.8% for D allele) or those up to three diseased vessels (0.7% for Y and 17.6% for D allele).
No significant difference was found in lipid levels or other classical risk factors with respect to the HFE genotype (data not shown).
Discussion
In our study, we found no indication that the C282Y and H63D mutations in the HFE gene are associated with increased risk of coronary atherosclerosis and MI.
When interpreting these results possible sources of bias must be considered. First, the study was case-controlled in design, and the subjects were not recruited prospectively. Therefore a survival bias cannot be excluded. However, assuming early mortality from CAD in individuals carrying HFE mutations, the latter would be over-represented in the control group. But it was not the case. We evaluated two independent groups of CAD-free controls, one of which was population-based. Even though angiography was not performed in population controls for ethical reasons, the use of the Rose questionnaire and ECGs to classify CAD patients in population-based screenings has been well established. 18 In addition, it must be noted that the pooled prevalence of HFE mutations in controls was comparable with that previously reported in Italian healthy subjects using the restriction enzyme technique. 19 The lack of association between HFE mutations and CAD may indicate that these genetic variants are not related to increased atherosclerosis. Similar conclusions were reached by Franco et al 20 In conclusion, our study did not provide evidence of a significant association between HFE mutations and the development of coronary atherosclerosis or its major ischemic complications, thus indicating that HFE mutations are poor genetic markers of risk in the general population of patients. 
